Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis—Reply

The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson... Letters Corresponding Author: Alexander Kreuter, MD, Department of Dermatology, revealed a complete clearance of all metastatic lymph nodes Venereology, and Allergology, Helios St Elisabeth Hospital Oberhausen, of her lung cancer. At that time, the scalp necrosis had almost University Witten/Herdecke, Josefstrasse 3, 46045 Oberhausen, Germany completely cleared. (alexander.kreuter@helios-kliniken.de). Published Online: July 17, 2019. doi:10.1001/jamadermatol.2019.1411 Discussion | Immune checkpoint inhibitors targeting PD-1 (pro- Conflict of Interest Disclosures: None reported. grammed cell death protein 1), such as nivolumab and pem- Additional Contributions: We thank the patient for granting permission to brolizumab, can induce a broad spectrum of immune-related publish this information. adverse events. Colitis, pneumonitis, nephritis, hypophysi- 1. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of tis, thyroiditis, and various cutaneous adverse events (com- the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125-128. doi:10. 1016/j.currproblcancer.2016.12.001 monly pruritus, vitiligo, lichenoid and morbilliform erup- 2. Cappelli LC, Shah AA, Bingham CO III. Cancer immunotherapy-induced tions, or eczema; less frequently acneiform eruptions, drug rheumatic diseases emerge as new clinical entities. RMD Open. 2016;2(2):e000321. reaction with eosinophilia, Stevens-Johnson syndrome, toxic doi:10.1136/rmdopen-2016-000321 epidermal necrolysis, bullous pemphigoid, cutaneous sarcoid- 3. Stucci S, Palmirotta R, Passarelli A, et al. Immune-related adverse events osis, or Sweet http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis—Reply

Loading next page...
 
/lp/american-medical-association/the-abcd-10-risk-prediction-model-for-in-hospital-mortality-among-1O0I2u0C1g
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2019.0998
Publisher site
See Article on Publisher Site

Abstract

Letters Corresponding Author: Alexander Kreuter, MD, Department of Dermatology, revealed a complete clearance of all metastatic lymph nodes Venereology, and Allergology, Helios St Elisabeth Hospital Oberhausen, of her lung cancer. At that time, the scalp necrosis had almost University Witten/Herdecke, Josefstrasse 3, 46045 Oberhausen, Germany completely cleared. (alexander.kreuter@helios-kliniken.de). Published Online: July 17, 2019. doi:10.1001/jamadermatol.2019.1411 Discussion | Immune checkpoint inhibitors targeting PD-1 (pro- Conflict of Interest Disclosures: None reported. grammed cell death protein 1), such as nivolumab and pem- Additional Contributions: We thank the patient for granting permission to brolizumab, can induce a broad spectrum of immune-related publish this information. adverse events. Colitis, pneumonitis, nephritis, hypophysi- 1. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of tis, thyroiditis, and various cutaneous adverse events (com- the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125-128. doi:10. 1016/j.currproblcancer.2016.12.001 monly pruritus, vitiligo, lichenoid and morbilliform erup- 2. Cappelli LC, Shah AA, Bingham CO III. Cancer immunotherapy-induced tions, or eczema; less frequently acneiform eruptions, drug rheumatic diseases emerge as new clinical entities. RMD Open. 2016;2(2):e000321. reaction with eosinophilia, Stevens-Johnson syndrome, toxic doi:10.1136/rmdopen-2016-000321 epidermal necrolysis, bullous pemphigoid, cutaneous sarcoid- 3. Stucci S, Palmirotta R, Passarelli A, et al. Immune-related adverse events osis, or Sweet

Journal

JAMA DermatologyAmerican Medical Association

Published: Oct 1, 2019

References